Wyeth To Revisit Launch Plans For Effexor XR Follow-On
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is waiting for results of lower dose desvenlafaxine studies, but says launch plans are not impacted by FDA's review extension.